|
| Monday, December 2, 2019 |
|
|
Eisai: Additional Indication for Lenvima (Lenvatinib) for Differentiated Thyroid Cancer Accepted in China |
| Eisai Co., Ltd. has announced that LENVIMA (generic name: lenvatinib), the orally available kinase inhibitor discovered by Eisai, has been accepted by the National Medical Products Administration of China for an application for the additional indication of differentiated thyroid cancer. more info >> |
|
| Tuesday, November 26, 2019 |
|
|
Eisai to Present Latest Data on Perampanel at the 73rd American Epilepsy Society Annual Meeting |
| Eisai Co., Ltd. has announced that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 73rd American Epilepsy Society Annual Meeting (AES 2019) to be held from December 6 to December 10, 2019 in Baltimore, Maryland in the United States. more info >> |
|
| Wednesday, November 20, 2019 |
|
|
Eisai's Equfina 50mg Tablets (Safinamide Mesilate) Launched in Japan |
| Eisai Co., Ltd. announced today that it has launched the Equfina 50mg TABLETS for the indication of improvement of the wearing-off phenomenon in patients with Parkinson's disease under treatment with a drug containing levodopa in Japan. more info >> |
|
| Tuesday, November 5, 2019 |
|
|
Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma |
| Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the rights to receive royalties on the sales outside of Japan for an investigational anti-cancer agent tazemetostat (generic name) to Royalty Pharma. more info >> |
|
| Wednesday, October 23, 2019 |
|
|
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies |
| Biogen and Eisai, Co., Ltd. has announced that, after consulting with the U.S. Food and Drug Administration (FDA), Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease (AD). more info >> |
|
| Tuesday, October 15, 2019 |
|
|
Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China |
| Eisai Co., Ltd. has announced that Eisai received a New Drug Approval for its in-house discovered and developed antiepileptic drug (AED) Fycompa (perampanel) from the China National Medical Products Administration (NMPA) for use in an adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older. more info >> |
|
| Tuesday, October 1, 2019 |
|
|
Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress |
| The findings were presented in a proffered paper presentation at the European Society for Medical Oncology (ESMO) 2019 Congress (Abstract #994O). more info >> |
|
| Monday, September 30, 2019 |
|
|
Eisai and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceutical Business in China |
| Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China. more info >> |
|
| Thursday, September 26, 2019 |
|
|
Eisai and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence and Prevention of Dementia |
| Eisai Co., Ltd. and Tokio Marine & Nichido Fire Insurance Co., Ltd. announced today that the companies have entered into a business alliance agreement for co-existence and prevention of dementia. more info >> |
|
|
Eisai and Fronteo to Launch Coroban Tumbling and Falling Prediction System for Inpatients |
| Eisai Co., Ltd. and FRONTEO, Inc. announced today that they have launched the tumbling and falling prediction system Coroban to medical institutions in Japan on September 26, 2019. more info >> |
|
|
|
